Filing Details
- Accession Number:
- 0001209191-20-020052
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-18 17:28:17
- Reporting Period:
- 2020-03-16
- Accepted Time:
- 2020-03-18 17:28:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1708493 | Harpoon Therapeutics Inc. | HARP | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1683811 | Natalie Sacks | C/O Harpoon Therapeutics, Inc. 131 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-03-16 | 1 | $2.12 | 45,755 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-03-16 | 1 | $12.00 | 45,754 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-03-17 | 1,520 | $2.12 | 47,274 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-03-17 | 1,520 | $12.00 | 45,754 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2020-03-16 | 1 | $0.00 | 1 | $2.12 |
Common Stock | Employee Stock Option (right to buy) | Disposition | 2020-03-17 | 1,520 | $0.00 | 1,520 | $2.12 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
50,188 | 2028-11-16 | No | 4 | M | Direct | |
48,668 | 2028-11-16 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.